Chronic hepatitis B

Asselah, Tarik; Lada, Olivier; Moucari, Rami; Marcellin, Patrick

doi:10.1002/9781118321386.ch80

Cited by 2 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the current study, independent predictors for HBeAg seroconversion include baseline HBV DNA replication of less than 7.5 log 10 IU/L (HR = 2.59 [1.04–6.44], P = 0.041) and ALT levels of greater than 1.5 × ULN (> 60 U/L) (HR = 2.86 [1.05–7.81], P = 0.040). No significant differences were found in HBeAg seroconversion rates among the four oral antiviral agents studied (Table ), although currently, ETV and TDF are considered first‐line oral agents given the high rates of resistance and other long‐term issues with earlier oral agents …”

Section: Discussionmentioning

confidence: 98%

Low incidence of hepatitis B e antigen seroconversion in patients treated with oral nucleos(t)ides in routine practice

Lin

Liu

et al. 2013

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 98%

Low incidence of hepatitis B e antigen seroconversion in patients treated with oral nucleos(t)ides in routine practice

Lin

Liu

et al. 2013

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

“…Globally, the number of people chronically infected with hepatitis B virus (HBV) has reached 400 million and up to 2 billion people are with the evidence of exposure. Approximately 3% of the world population is infected by HCV or about 170 million people are HCV-infected [7, 8]. The liver is a very complex organ that is essential for living.…”

Section: Introductionmentioning

confidence: 99%

A Current Update on the Rule of Alternative and Complementary Medicine in the Treatment of Liver Diseases

Guan

2013

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

There is a vast body of knowledge which is ever-increasing about the treatment of liver disease with alternative and complementary medicine for which hundreds of thousands of literatures have been documented. Liver disease is a general term. This term covers all the potential problems that cause the liver to fail to perform its specified operations. Liver disease has a variety of presentations and causes a great public health problem worldwide which threatens the wellness of billions of people. Incidences of many types of liver disease are currently rising. Although there is still a debate about the entity of alternative and complementary medicine, it is now widely used and it is improving. And it covers the shortages and compensates for the weaknesses of conventional methods in the treatment of liver diseases. Alternative and complementary medicine for liver diseases provides benefits by regulating immunity, controlling disease progression, improving quality of life, and prolonging survival. This paper reviews the increasing interest and growing research into alternative and complementary medicine for liver diseases, with a look at the rough classification, principle of management, evidence-based applications, and issues for prescription and perspectives.

show abstract

Chronic hepatitis B

Cited by 2 publications

References 26 publications

Low incidence of hepatitis B e antigen seroconversion in patients treated with oral nucleos(t)ides in routine practice

Low incidence of hepatitis B e antigen seroconversion in patients treated with oral nucleos(t)ides in routine practice

A Current Update on the Rule of Alternative and Complementary Medicine in the Treatment of Liver Diseases

Contact Info

Product

Resources

About